Stock MAIA MAIA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights MAIA Biotechnology, Inc.

Equities

MAIA

US5526411021

Market Closed - Nyse
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
3.42 USD +2.70% Intraday chart for MAIA Biotechnology, Inc. -0.29% +192.31%
06-07 MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies DJ
06-07 MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA?s Approval of a Telomerase Inhibitor Agent Therapy CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies
DJ
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA?s Approval of a Telomerase Inhibitor Agent Therapy
CI
Maia Biotechnology Reveals New Clinical Data Showing Thio?s Strong Efficacy in Non-Small Cell Lung Cancer
CI
MAIA Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
CI
MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC
CI
MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
CI
MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
CI
Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds
CI
MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
CI
MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
CI
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
CI
MAIA Biotechnology Says Glioblastoma Treatment Gets Orphan-Drug Designation From US FDA
MT
Tranche Update on MAIA Biotechnology, Inc.'s Equity Buyback Plan announced on September 28, 2023.
CI
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
CI
MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
CI
MAIA Biotechnology, Inc. Announces Potent Anticancer Activity of THIO in Gliomas
CI
MAIA Biotechnology, Inc. Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MAIA Stock
  4. News MAIA Biotechnology, Inc.
  5. Highlights